Recent U.S. funding cuts to AIDS programs have sparked alarms, with UNAIDS warning of potential catastrophic rises in HIV infections and AIDS-related deaths. The future of global health hangs in the balance.
A groundbreaking HIV prevention shot, Yeztugo, has been approved by the FDA, offering hope for at-risk individuals with its twice-yearly injections. However, concerns about cost and accessibility remain.
The FDA has approved Gilead's Yeztugo, a twice-yearly injection that could revolutionize HIV prevention, boasting a 99.9% effectiveness. While hailed as a breakthrough, concerns over pricing remain, with activists urging for affordability.
The U.S. has approved a groundbreaking twice-a-year shot, lenacapvir, for HIV prevention, potentially transforming care. Experts suggest this could significantly reduce new infections.
